Table 2 Overview of endpoints conducted in OECD 408 studies for Oct-1-ene, Nonene, branched, Octadec-1-ene, Octadecene, and hydrocarbons, C12-30, olefin-rich, ethylene polymn. by-product
From: The subchronic toxicity of higher olefins in Han Wistar rats
Substances | Oct-1-ene | Nonene, branched | Octadec-1-ene | Octadecene | Hydrocarbons, C12-30, olefin-rich, ethylene polymn. by product |
|---|---|---|---|---|---|
Dose level (mg/kg) | 0, 100, 300 and 1000 | 0, 20, 100 and 500 | 0, 20, 100 and 500 | 0, 100, 300 and 1000 | 0, 100, 300 and 1000 |
Mortality | No unscheduled deaths | No unscheduled deaths | No unscheduled deaths | No unscheduled deaths | No unscheduled deaths |
Clinical observations | Either sex treated with 1000 and 300 mg/kg bw/day showed episodes of increased salivation during the treatment period. | Either sex treated with 500 and 100 mg/kg bw/day showed episodes of increased salivation during the treatment period. | Either sex treated with 500 mg/kg bw/day showed episodes of increased salivation between Days 27 and 50 for males and between Days 27 and 90 for females. | Either sex treated with 1000 mg/kg bw/day showed episodes of increased salivation during the treatment period. | No clinical signs observed |
Behavioral assessment | No treatment-related changes | No treatment-related changes | No treatment-related changes | No treatment-related changes | No treatment-related changes |
Functional performance | No toxicologically significant changes | No toxicologically significant changes | No toxicologically significant changes | No toxicologically significant changes | No toxicologically significant changes |
Sensory reactivity assessments | No treatment-related changes | No treatment-related changes | No treatment-related changes | No treatment-related changes | No treatment-related changes |
Body weight | No effect on body weight performance | No effect on body weight performance | No effect on body weight performance | No effect on body weight performance | No effect on body weight performance |
Food consumption | No treatment-related effects on food consumption or food conversion efficiency | No treatment-related effects on food consumption or food conversion efficiency | No treatment-related effects on food consumption or food conversion efficiency | No treatment-related effects on food consumption or food conversion efficiency | No treatment-related effects on food consumption or food conversion efficiency |
Water consumption | No treatment-related effect | No treatment-related effect | No treatment-related effect | No treatment-related effect | No treatment-related effect |
Ophthalmoscopy | No treatment-related ocular effects | No treatment-related ocular effects | No treatment-related ocular effects | No treatment-related ocular effects | No treatment-related ocular effects |
Hematology | No toxicologically significant effects | No toxicologically significant effects | Males treated with 500 mg/kg bw/day showed a statistically significant reduction in prothrombin time and activated partial thromboplastin time | No toxicologically significant effects | No toxicologically significant effects |
Blood chemistry | No toxicologically significant effects | No toxicologically significant effects | No toxicologically significant effects | No toxicologically significant effects | No toxicologically significant effects |
Necropsy | No toxicologically significant macroscopic abnormalities | Three males treated with 500 mg/kg bw/day had enlarged kidneys. Two further males treated with 500 mg/kg bw/day had pale kidneys and one of these males also had mottled kidneys. All males treated with 500 mg/kg bw/day and three males treated with 100 mg/kg bw/day had an enlarged liver. | No toxicologically significant macroscopic abnormalities | Neither the type, incidence nor distribution of findings observed at terminal necropsy indicated any obvious effect of treatment | Neither the type, incidence nor distribution of findings observed at terminal necropsy indicated any obvious effect of treatment |
Organ weights | Males treated 1000 mg/kg bw/day and females from all treatment groups showed a statistically significant increase in liver weight both absolute and relative to terminal body weight Males treated with 1000 mg/kg bw/day showed a statistically significant reduction in epididymides weight both absolute and relative to terminal body weight | Males treated with 500 and 100 mg/kg bw/day showed a statistically significant increase in kidney and liver weights both absolute and relative to terminal body weight. Females treated with 500 mg/kg bw/day also showed a statistically significant increase in absolute and relative liver weight. Females from all treatment groups showed a statistically significant increase in absolute and relative kidney weight. Males treated with 100 and 20 mg/kg bw/day showed a statistically significant reduction in spleen weight both absolute and relative to terminal body weight | Males from all treatment groups showed a statistically significant reduction in spleen weight both absolute and relative to terminal body weight. Males treated with 500 mg/kg bw/day showed a statistically significant increase in absolute and relative thymus weight. Females treated with 500 mg/kg bw/day showed a statistically significant increase in absolute and relative liver weight. | No effects in the organ weights | No effects in the organ weights |
Histopathology | Kidneys: increased incidence and severity of hyaline droplets and granular casts were evident in males from all treatment groups. Stomach: Acanthosis, hyperkeratosis, ulceration and submucosal inflammation was evident in the forestomach of animals of either sex treated with 1000 and 300 mg/kg bw/day. Lungs: increased incidence and severity of alveolar macrophages were evident in animals of either sex treated with 1000 mg/kg bw/day and in females treated with 100 mg/kg bw/day. | Kidneys: hyaline droplets and tubular basophilia was evident in males from all treatment groups. Granular casts were also evident in males treated with 500 and 100 mg/kg bw/day. Liver: centrilobular hypertrophy was evident in animals of either sex treated with 500 and 100 mg/kg bw/day. Thyroid: hypertrophy/hyperplasia of follicular cells was evident in animals of either sex treated with 500 and 100 mg/kg bw/day. Stomach: acanthosis of the forestomach was evident at extremely low severity in males treated with 500 mg/kg bw/day. | Mesenteric Lymph nodes: A minimal or mild inflammatory cell infiltrate was present in the periglandular fat surrounding the mesenteric lymph nodes of eight males and nine females treated with 500 mg/kg bw/day. Adrenals: Minimal diffuse hypertrophy of the adrenal cortex was present in two females treated with 500 mg/kg bw/day. | No abnormal findings observed during microscopic examination | No abnormal findings observed during microscopic examination |
No Observed Effect Level (NOEL) | Male: Not established Female: 100 mg/kg bw/day | Male: Not established Female: 20 mg/kg bw/day | 100 mg/kg bw/day for both sexes | 1000 mg/kg bw/day for both sexes | 1000 mg/kg bw/day for both sexes |
No Observed Adverse Effect Level (NOAEL) | 1000 mg/kg bw/day for both sexes | 500 mg/kg bw/day for both sexes | 500 mg/kg bw/day for both sexes | 1000 mg/kg bw/day for both sexes | 1000 mg/kg bw/day for both sexes |